UCB SA (UCBJF)
OTCMKTS · Delayed Price · Currency is USD
276.21
-16.48 (-5.63%)
At close: Mar 20, 2026
UCB SA Revenue
In the year 2025, UCB SA had annual revenue of 7.74B EUR with 25.83% growth. UCB SA had revenue of 4.25B in the half year ending December 31, 2025, with 59.74% growth.
Revenue
7.74B EUR
Revenue Growth
+25.83%
P/S Ratio
5.97
Revenue / Employee
792.73K EUR
Employees
9,765
Market Cap
54.28B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.74B | 1.59B | 25.83% |
| Dec 31, 2024 | 6.15B | 900.00M | 17.14% |
| Dec 31, 2023 | 5.25B | -265.00M | -4.80% |
| Dec 31, 2022 | 5.52B | -260.00M | -4.50% |
| Dec 31, 2021 | 5.78B | 430.00M | 8.04% |
| Dec 31, 2020 | 5.35B | 434.00M | 8.83% |
| Dec 31, 2019 | 4.91B | 281.00M | 6.07% |
| Dec 31, 2018 | 4.63B | 102.00M | 2.25% |
| Dec 31, 2017 | 4.53B | 383.00M | 9.24% |
| Dec 31, 2016 | 4.15B | 271.00M | 6.99% |
| Dec 31, 2015 | 3.88B | 532.00M | 15.91% |
| Dec 31, 2014 | 3.34B | 211.00M | 6.73% |
| Dec 31, 2013 | 3.13B | -329.00M | -9.50% |
| Dec 31, 2012 | 3.46B | 216.00M | 6.65% |
| Dec 31, 2011 | 3.25B | 28.00M | 0.87% |
| Dec 31, 2010 | 3.22B | 102.00M | 3.27% |
| Dec 31, 2009 | 3.12B | -485.00M | -13.47% |
| Dec 31, 2008 | 3.60B | -25.00M | -0.69% |
| Dec 31, 2007 | 3.63B | 1.08B | 42.14% |
| Dec 31, 2006 | 2.55B | 210.00M | 8.97% |
| Dec 31, 2005 | 2.34B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 292.21M |
| Vaxart | 237.26M |
| Nuo Therapeutics | 2.61M |
| Northwest Biotherapeutics | 937.00K |
| Silence Therapeutics | 559.00K |
| ZIVO Bioscience | 209.03K |
UCB SA News
- 9 days ago - Ex-Div Reminder for United Community Banks (UCB) - Nasdaq
- 9 days ago - UCB's Bimzelx Outperforms AbbVie's Skyrizi in Psoriatic Arthritis Trial - GuruFocus
- 17 days ago - Belgium's UCB in autoimmune drug deal with Antengene - Reuters
- 18 days ago - UCB SA (UCBJF) (FY 2025) Earnings Call Highlights: Record Growth and Strategic Investments ... - GuruFocus
- 18 days ago - Full Year 2025 Ucb SA Earnings Call Transcript - GuruFocus
- 18 days ago - Best Income Stocks to Buy for March 2nd - Nasdaq
- 4 months ago - U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d) - PRNewsWire